MedTrace Logo

FolateScan in Autoimmune Disease

NCT00588393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-04-16

No results posted yet for this study

Summary

This study will gather information on the safety of FolateScan and the ability of FolateScan to detect inflammation in the joints and other organs in people with arthritis (rheumatoid arthritis and osteoarthritis), systemic lupus erythematosus, multiple sclerosis, interstitial pneumonitis, Crohn's disease as well as in healthy persons without these conditions.

Conditions

Interventions

DRUG

FolateScan (Technetium Tc 99mEC20)

0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan

Sponsors & Collaborators

  • Endocyte

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Eric L Matteson, M.D., M.P.H. · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00588393 on ClinicalTrials.gov